BASEL, Switzerland, April 15, 2003 (PRIMEZONE) -- Novartis (NYSE:NVS) (Other OTC:NVSEF):
-- Group sales up 21% in USD (13% in local currencies); Pharmaceuticals grows by 18% in USD (10% in local currencies); Generics jumps 98% in USD (83% in local currencies) -- Group operating income climbs 24%, lifted by further productivity and product mix enhancements -- Net income at previous first quarter level due to impact of 2002 loss at associated company Roche, excluding which net income would have increased 27% -- Increased investment in R&D and successful Business Development/Licensing deals add to attractive pipeline